MX2023005654A - Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza. - Google Patents
Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza.Info
- Publication number
- MX2023005654A MX2023005654A MX2023005654A MX2023005654A MX2023005654A MX 2023005654 A MX2023005654 A MX 2023005654A MX 2023005654 A MX2023005654 A MX 2023005654A MX 2023005654 A MX2023005654 A MX 2023005654A MX 2023005654 A MX2023005654 A MX 2023005654A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies against
- neutralizing antibodies
- against influenza
- broadly neutralizing
- influenza neuraminidase
- Prior art date
Links
- 102000005348 Neuraminidase Human genes 0.000 title abstract 3
- 108010006232 Neuraminidase Proteins 0.000 title abstract 3
- 206010022000 influenza Diseases 0.000 title abstract 2
- 230000003472 neutralizing effect Effects 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 2
- 108091033319 polynucleotide Proteins 0.000 abstract 2
- 239000002157 polynucleotide Substances 0.000 abstract 2
- 241000712461 unidentified influenza virus Species 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La presente invención se refiere a anticuerpos y fragmentos de unión al antígeno de los mismos que pueden unirse a una neuraminidasa (NA) del virus de la influenza y pueden neutralizar una infección por el virus de la influenza. También se proporcionan polinucleótidos que codifican un anticuerpo, vectores que comprenden tales polinucleótidos, células hospederas que pueden expresar los anticuerpos, composiciones relacionadas y métodos para usar las composiciones descritas en el presente documento para, por ejemplo, tratar o prevenir una infección por influenza.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063117448P | 2020-11-23 | 2020-11-23 | |
| US202063123424P | 2020-12-09 | 2020-12-09 | |
| US202163197160P | 2021-06-04 | 2021-06-04 | |
| US202163261463P | 2021-09-21 | 2021-09-21 | |
| PCT/US2021/060155 WO2022109309A1 (en) | 2020-11-23 | 2021-11-19 | Broadly neutralizing antibodies against influenza neuraminidase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005654A true MX2023005654A (es) | 2023-07-31 |
Family
ID=79021106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005654A MX2023005654A (es) | 2020-11-23 | 2021-11-19 | Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20240092876A1 (es) |
| EP (1) | EP4247495A1 (es) |
| JP (1) | JP2023551668A (es) |
| KR (1) | KR20230137293A (es) |
| AU (1) | AU2021381778A1 (es) |
| CA (1) | CA3199023A1 (es) |
| CL (1) | CL2023001462A1 (es) |
| CO (1) | CO2023007527A2 (es) |
| IL (1) | IL302963A (es) |
| MX (1) | MX2023005654A (es) |
| TW (1) | TW202229329A (es) |
| WO (1) | WO2022109309A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023230445A2 (en) * | 2022-05-23 | 2023-11-30 | Humabs Biomed Sa | Broadly neutralizing antibodies against influenza neuraminidase |
| WO2024081953A2 (en) * | 2022-10-14 | 2024-04-18 | Longhorn Vaccines And Diagnostics, Llc | Vaccines and antibodies for the treatment and prevention of microbial infections |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL7803C (es) | ||||
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0861893A3 (en) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | High level expression of immunoglobulin polypeptides |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
| KR100797667B1 (ko) | 1999-10-04 | 2008-01-23 | 메디카고 인코포레이티드 | 외래 유전자의 전사를 조절하는 방법 |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| EP1597280B2 (en) | 2003-02-26 | 2016-08-24 | Institute for Research in Biomedicine | Monoclonal antibody production by ebv transformation of b cells |
| DE602004030700D1 (de) | 2003-09-24 | 2011-02-03 | Kyowa Hakko Kirin Co Ltd | Rekombinanter antikörper gegen humanen insulin-like growth factor |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US8119772B2 (en) | 2006-09-29 | 2012-02-21 | California Institute Of Technology | MART-1 T cell receptors |
| BR112016015140A2 (pt) | 2013-12-30 | 2018-01-23 | Epimab Biotherapeutics Inc. | imunoglobulina com fabs in-tandem e usos das mesmas |
| US10072070B2 (en) * | 2014-12-05 | 2018-09-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Potent anti-influenza A neuraminidase subtype N1 antibody |
| JP6587696B2 (ja) | 2015-05-13 | 2019-10-09 | ズムトール バイオロジクス、インコーポレイテッド | アフコシル化タンパク質、前記タンパク質を発現する細胞、及び関連する方法 |
| WO2018187706A2 (en) * | 2017-04-07 | 2018-10-11 | Icahn School Of Medicine At Mount Sinai | Anti-influenza b virus neuraminidase antibodies and uses thereof |
| WO2019024979A1 (en) | 2017-07-31 | 2019-02-07 | Institute For Research In Biomedicine | FUNCTIONAL DOMAIN ANTIBODIES IN THE ELBOW REGION |
| SG11202002261VA (en) | 2017-09-22 | 2020-04-29 | Wuxi Biologics Ireland Ltd | Novel bispecific polypeptide complexes |
| EP3787678A1 (en) * | 2018-05-03 | 2021-03-10 | University Of Rochester | Anti-influenza neuraminidase monoclonal antibodies and uses thereof |
-
2021
- 2021-11-19 KR KR1020237021242A patent/KR20230137293A/ko unknown
- 2021-11-19 TW TW110143246A patent/TW202229329A/zh unknown
- 2021-11-19 MX MX2023005654A patent/MX2023005654A/es unknown
- 2021-11-19 EP EP21830556.3A patent/EP4247495A1/en active Pending
- 2021-11-19 US US18/253,385 patent/US20240092876A1/en active Pending
- 2021-11-19 CA CA3199023A patent/CA3199023A1/en active Pending
- 2021-11-19 WO PCT/US2021/060155 patent/WO2022109309A1/en active Application Filing
- 2021-11-19 JP JP2023531064A patent/JP2023551668A/ja active Pending
- 2021-11-19 AU AU2021381778A patent/AU2021381778A1/en active Pending
- 2021-11-19 IL IL302963A patent/IL302963A/en unknown
-
2023
- 2023-05-22 CL CL2023001462A patent/CL2023001462A1/es unknown
- 2023-06-07 CO CONC2023/0007527A patent/CO2023007527A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022109309A9 (en) | 2022-09-01 |
| CL2023001462A1 (es) | 2023-10-20 |
| EP4247495A1 (en) | 2023-09-27 |
| CO2023007527A2 (es) | 2023-08-18 |
| TW202229329A (zh) | 2022-08-01 |
| WO2022109309A1 (en) | 2022-05-27 |
| KR20230137293A (ko) | 2023-10-04 |
| US20240092876A1 (en) | 2024-03-21 |
| CA3199023A1 (en) | 2022-05-27 |
| JP2023551668A (ja) | 2023-12-12 |
| AU2021381778A1 (en) | 2023-06-22 |
| IL302963A (en) | 2023-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020007888A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| PH12021550793A1 (en) | Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments | |
| PH12020550214A1 (en) | Antibodies specific to cd47 and pd-l1 | |
| MX2020009366A (es) | Anticuerpos anti-cd73 y usos de los mismos. | |
| BR112022017048A2 (pt) | Anticorpos contra sars-cov-2 e métodos para usar os mesmos | |
| MX2023005654A (es) | Anticuerpos ampliamente neutralizantes contra neuraminidasa de la influenza. | |
| MX2022013886A (es) | Anticuerpos contra coronavirus de tipo 2 causante del sindrome respiratorio agudo severo (sars-cov-2). | |
| WO2018234793A3 (en) | Antibodies | |
| PH12019501973A1 (en) | Anti-phf-tau antibodies and uses thereof | |
| AU2017297757A1 (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| MX2021005708A (es) | Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos. | |
| WO2021212049A3 (en) | Anti-sars-cov-2 monoclonal antibodies | |
| WO2019014328A3 (en) | AGONISTIC ANTIBODIES THAT BIND HUMAN CD137 AND USES THEREOF | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| MX2023005653A (es) | Anticuerpos contra los virus de la influenza a. | |
| MX2022009476A (es) | Anticuerpos anti-tmprss2 y fragmentos de union a antigeno. | |
| WO2018194496A3 (ru) | Моноклональное антитело к pd-l1 | |
| BR112022020706A2 (pt) | Anticorpos contra sars-cov-2 e métodos de uso dos mesmos | |
| PL422231A1 (pl) | Komórki immunologiczne CAR do leczenia nowotworów | |
| MX2022014598A (es) | Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno. | |
| MX2021005323A (es) | Metodos de tratar la oftalmopatía de graves mediante el uso de anticuerpos anti-fcrn. | |
| MX2021005345A (es) | Composiciones y metodos. | |
| MX2022012628A (es) | Anticuerpos anti-phf-tau y usos de estos. | |
| EA202092125A1 (ru) | Антитела против рецептора фолата 1 и их применения | |
| MX2023011788A (es) | Anticuerpos contra ilt4, anticuerpo biespecifico anti-ilt4/pd-l1 y usos de los mismos. |